Speciality Medicines IPO Listing 2026 – Allotment, Demat Credit & BSE SME Debut

The Speciality Medicines Limited IPO is a book‑building public issue that opened for subscription on March 20, 2026 and closed on March 24, 2026. The offer is entirely a fresh issue, aiming to raise about ₹29.14 crore from investors. The IPO price band was fixed at ₹117–₹124 per share, and the minimum market lot is 2,000 shares, requiring an investment of around ₹2.48 lakh at the upper band. The basis of allotment was finalised on March 25, 2026, with refund processing and demat credit scheduled for March 27, 2026. Shares are set to be listed on the BSE SME platform on March 30, 2026. The IPO was open to various investor categories including retail, HNI (High Net Worth Individual), and institutional segments.

Speciality Medicines IPO Listing Details

Image Reference : https://www.bseindia.com/

About Speciality Medicines Limited

Speciality Medicines Limited is a pharmaceutical distribution and marketing company based in Ahmedabad, Gujarat, India, founded in 2021. The company specialises in the marketing, trading, and distribution of specialty pharmaceutical products, particularly high‑cost oral and injectable medications used to treat complex and chronic health conditions across therapeutic areas such as oncology, immunology, neurology, and rare diseases. It sources products from established manufacturers and supplies them across India and internationally, with a presence in over 20 Indian states and multiple global markets. Over recent years, the company has shown strong financial growth, with revenue rising from around ₹27.66 crore in FY24 to ₹58.54 crore in FY25 and profit after tax increasing from ₹2.93 crore to ₹8.61 crore during the same period. The IPO proceeds are expected to fund initiatives like setting up an R&D centre, product registrations in international markets, working capital needs, and other corporate purposes.